Cancer Genetics (NASDAQ:CGIX) Coverage Initiated by Analysts at initiated coverage on shares of Cancer Genetics (NASDAQ:CGIXGet Rating) in a report released on Monday. The brokerage set a “sell” rating on the stock.

Shares of NASDAQ:CGIX opened at $4.61 on Monday. Cancer Genetics has a 52-week low of $2.11 and a 52-week high of $17.50. The firm has a 50 day moving average price of $0.96.

About Cancer Genetics (Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.